What PDU­FA date? Clo­vis shares surge as PARPs get trendy on Wall Street

Yes­ter­day was the of­fi­cial PDU­FA date for Clo­vis On­col­o­gy’s rocile­tinib. But the com­pa­ny — now main­tain­ing very low vis­i­bil­i­ty — let it slide past with­out for­mal­ly an­nounc­ing a re­jec­tion that had al­ready been flagged from an ear­li­er com­mu­ni­ca­tion with the agency.

Clo­vis’ shares ($CLVS), though, jumped 20% this morn­ing. Why?

That has to do with the spike in Tesaro’s shares ($TSRO), which soared in the wake of pro­gres­sion-free-sur­vival among pa­tients tak­ing ni­ra­parib, its PARP in­hibitor. Clo­vis has a late-stage PARP in­hibitor, ru­ca­parib, and Tesaro’s win helped boost the Boul­der, CO-based biotech’s bat­tered stock.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.